April 26, 2024
Bio
Handok inks W10b deal to export Ketotop
[THE INVESTOR] South Korean pharmaceutical company Handok is seeking to enter the Southeast Asian market with its flagship arthritis relieving patch Ketotop.
The firm signed a 10 billion won (US$8.52 million) contract with Zuellig Pharma, a health care distributor, to sell Ketotop in Singapore and Malaysia, Handok said Nov. 22.
The firm signed a 10 billion won (US$8.52 million) contract with Zuellig Pharma, a health care distributor, to sell Ketotop in Singapore and Malaysia, Handok said Nov. 22.
 |
“We believe that Ketotop has a great potential to become a top brand in the nonsteroidal anti-inflammatory drug market, given that it has topped the domestic market for the last 22 years since its launch in 1994,” said Handok Chairman Kim Young-jin.
Ketotop is a plaster pain relieving patch for patients with arthritis and muscular pain.
Handok and Zuellig Pharma will commence sale of the drug in the two countries next year and plan to tap into other regional markets including Vietnam and the Philippines.
By Park Han-na (hnpark@heraldcorp.com)
![[KH Explains] Korean shipbuilding stocks rally: Real growth or bubble?](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=151&simg=/content/image/2024/04/25/20240425050656_0.jpg)
![[Hello India] Hyundai Motor vows to boost 'clean mobility' in India](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=151&simg=/content/image/2024/04/25/20240425050672_0.jpg)
